Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | CHRND | Q07001 | 6/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.38 |
| ▸ | CHRNG | P07510 | 2/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31087110 | 0.84 | GNAI3 (0.40) | GNAI3GNAO1GNAI1SIRT6SIRT1 | |
| SCHEMBL30469041 | 0.83 | TDP1 (0.47) | — | |
| SCHEMBL18165057 | 0.74 | PAOX (0.39) | SIRT6SIRT1PAOXCHRNDCHRNA1 | |
| SCHEMBL28646996 | 0.74 | TSHR (0.35) | GNAI3GNAO1GNAI1SIRT6SIRT1 | |
| SCHEMBL31087117 | 0.73 | TDP1 (0.47) | — | |
| SCHEMBL25935771 | 0.73 | PAOX (0.50) | GNAI3GNAO1GNAI1SIRT6SIRT1 | |
| SCHEMBL18161922 | 0.71 | HDAC3 (0.35) | CHRNDCHRNA1CHRNGCHRNB1GRIA1 | |
| SCHEMBL25268047 | 0.71 | DNMT1 (0.41) | — | |
| SCHEMBL31087099 | 0.71 | DNMT1 (0.41) | — | |
| SCHEMBL25219511 | 0.71 | DNMT1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| CN-118591393-A | Antibody conjugated chemical degradation inducers with hydrolyzable maleimide linkers and methods thereof | 基因泰克公司 | 2024-09-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | LGMN, B2M, HNMT | GNAI3 3096/4885GNAO1 3674/4885GNAI1 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.